Brought to you by 
Series C round brings $45.9mm to Otonomy
27 Sep 2013
Executive Summary
Otonomy Inc. (developing controlled-release drugs for inner ear conditions) raised $45.9mm through its Series C round. OrbiMed Advisors led (and takes a board seat) and was joined by new investors Aperture Venture Partners and Osage University Partners. Also participating were returning backers Avalon Ventures, Domain Associates, Novo Ventures, RiverVest Venture Partners, and TPG Biotech. Proceeds will fund upcoming Phase II trials of OTO104 for Ménière's disease and OTO201, an antibiotic for children with otitis media and effusion at the time of tympanostomy tube replacement surgery. Funds will also help propel preclinical candidates into trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C round brings $45.9mm to Otonomy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice